Background: Persistent low-level viraemia (PLLV) is a risk factor for virologic failure among
people receiving antiretroviral therapy (ART). Objectives: We assessed the prevalence and …

We evaluated subsequent virologic outcomes in individuals experiencing low-level virem ia
(LLV) on dolutegravir (DTG)-based first-line antiretroviral therapy (ART) in Botswana. We …

Objectives The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are
rarely investigated among people living with HIV (PLWH) receiving dolutegravir-vs protease …

Background HIV low-level viremia (LLV)(51–999 copies/mL) can progress to treatment
failure and increase potential for drug resistance. We analyzed retrospective longitudinal …

Background We aimed to compare clinical outcomes after viremia between dolutegravir vs
efavirenz-based first-line antiretroviral therapy (ART) as evidence is lacking outside clinical …

Background Transitioning to dolutegravir-based therapy in Cameroon has improved viral
suppression (VS) rates, known as low-level viremia (LLV)< 1000copies/ml. However, there …

Background We evaluated the treatment outcomes of individuals experiencing low-level
viremia (LLV) on dolutegravir (DTG) based first-line antiretroviral therapy (ART) in Botswana …

Background HIV is one of the leading causes of morbidity and mortality, with 39.0 million
people living with HIV worldwide, 25.6 million of whom reside in the African region. Highly …

There have been limited studies linking baseline factors, including the viral load (VL) test,
with virological non-suppression since the introduction of dolutegravir (DTG)-based …

Background Human immunodeficiency virus low-level viremia (LLV) is associated with
subsequent treatment failure at least with non nucleoside reverse transcriptase inhibitor …